while 2 years might look ok compared to industry, if you realise this is a basically only “drug release modification of existing drugs so phase 1 should be very quick and so should phase 2. If can’t recruit fast on this type of follow on modified drug product then there is something wrong and management don’t understand that in biotech time is money and can’t ware time dithering. Patent are running out of time and competitors Overtake get better product to market. Hurry up little horse you are loosing the race and will be euthanised if you don’t get to the finiish line very soon.
SPL Price at posting:
93.0¢ Sentiment: None Disclosure: Held
(20min delay)